PEG10 as an oncogene: expression regulatory mechanisms and role in tumor progression

Table 2 Basic information of the 14 GEO datasets

Cancer type	Accession number	Number of samples (tumor/normal)	P-value	References
Upregulated
Hepatocellular carcinoma	GSE14520	233/233	< 0.0001	[57, 58]
Breast carcinoma	GSE10780	42/143	0.0002	[59]
Gastric cancer	GSE13861	71/19	0.0388	[60]
Ovarian cancer	GSE14407	12/12	0.0438	[61]
Downregulated
Pancreatic cancer	GSE28735	45/45	0.0003	[62, 63]
Colorectal cancer	GSE32323	17/17	0.0011	[64]
Insignificant
Melanoma	GSE3189	45/7	0.0848	[65]
Bladder cancer	GSE3167	41/9	0.1243	[66]
Acute lymphoblastic leukemia	GSE26713	117/7	0.2168	[67]
Renal clear cell carcinoma	GSE36895	23/23	0.2445	[68]
Esophageal carcinoma	GSE23400	53/53	0.2526	[69, 70]
Nasopharyngeal carcinoma	GSE12452	31/10	0.2710	[71,72,73]
Lung cancer	GSE30219	293/14	0.2938	[74]
Prostate cancer	GSE6919	58/58	0.7478	[75, 76]

P-values were acquired through t-test for the comparison of PEG10 expression between cancer and normal

ISSN: 1475-2867